Enovis Corporation (ENOV)

Enovis Corp.'s stock price has been impacted by several events in the past six months. The Q3 2025 earnings report showed an EPS of $0.75 and revenue of $548.91 million, both exceeding estimates. The company reported a Q3 2025 net loss of $571 million due to a non-cash goodwill impairment charge of $548 million. Enovis Corporation was dropped from the Russell Midcap Index on June 29, 2025. Damien McDonald became CEO on May 12, 2025. Over the past year, ENOV underperformed the US Medical Equipment industry and the broader US Market, with the share price declining by 51.89% to $23.09 as of January 20, 2026.

Information regarding the specific demand seasonality for Enovis Corp.'s products and services was not explicitly available. The Prevention & Recovery segment may experience more consistent demand, while the Reconstructive segment could be influenced by factors affecting elective surgery volumes.

Enovis Corporation is a medical technology company focused on musculoskeletal health, operating in the healthcare sector, specifically the medical devices industry. Established in April 2022 after a spin-off from Colfax Corporation, it has two primary segments: Reconstructive, focusing on surgical implants and advanced surgical technologies, and Prevention & Recovery, offering orthopedic solutions and recovery sciences.

Enovis has a global presence, serving customers in the United States and other countries. It maintains facilities across Europe, Asia, South America, and the Middle East. The acquisition of LimaCorporate S.p.A. in 2024 significantly expanded its international footprint, with international sales accounting for almost 50% of total sales.

Enovis positions itself as an innovation-driven medical technology growth company and a challenger brand in the orthopedic market, aiming to shape the future of orthopedic care. Its mission is centered on restoring patient mobility through clinically differentiated medical technology and enhancing patient outcomes globally. The company emphasizes a culture of continuous improvement and a commitment to Creating Better Together. No specific events negatively impacting Enovis Corp.'s brand reputation in the past year were found.

Enovis Corporation's ownership is heavily concentrated among institutional investors, who hold nearly all of the company's outstanding shares (98.9%). Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and American Century Companies Inc. Individual insiders hold about 1.08% of the shares, while retail and other investors account for the remaining 0.02%.